The real “commercial launch” happens years before launch preparation officially begins. Once Phase III begins, your evidence ...

PRISM aims to operationalise readiness as a core execution variable.

In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of ...

ConcertAI, a leading oncology real-world evidence and AI SaaS technology company, today unveiled Accelerated Clinical Trials (ACT), an enterprise agentic artificial intelligence (AI) platform designed ...

As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards (“IRBs”) with defining, identifying, and reporting ...

At this year's conference, TransCelerate and representatives from its member companies, including Amgen, Merck, and Pfizer, will participate in seven sessions addressing topics such as data collection ...

Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from ...

Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapyTraumatic ...

TARPON SPRINGS, Fla., June 2, 2025-- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

Spanish healthtech company Biorce has secured $52.5m through a Series A funding round to support the global rollout of its ...